Advertisement

Uro-News

, Volume 21, Issue 5, pp 22–26 | Cite as

Prädiktive Biomarker beim Prostatakarzinom

Androgenrezeptor-Spleißvariante AR-V7: Implikationen für die Praxis

  • Julie Steinestel
Fortbildung
  • 13 Downloads

Mittlerweile stehen verschiedene Therapeutika zur Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms zur Verfügung. Allen gemeinsam ist, dass das Ansprechen des Patienten und auch die Dauer des Ansprechens auf die verschiedenen Therapeutika, bisher nicht vorausgesagt werden kann. Ein geeigneter prädiktiver Biomarker, der dieses Problem löst, wird gesucht. Dabei wird auch die Androgenrezeptor-Spleißvariante AR-V7 als Option gehandelt.

Literatur

  1. 1.
    Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci. 2008; 121: 957–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Yu Z, Chen S, Sowalsky AG, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20: 1590–600.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013; 73: 483–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72: 3457–62.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68: 5469–77.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, et al. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res. 2015; 75: 3663–71.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 3213–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9: 997–1007.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pantel K, Speicher M. The biology of circulating tumor cells. Oncogene. 2016; 35: 1216–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 2012: 883–92.CrossRefGoogle Scholar
  11. 11.
    Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371: 1028–38.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015 [Epub ahead of print].Google Scholar
  13. 13.
    Steinestel J, Schrader AJ, Luedeke M. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med. 2014; 371: 2234.PubMedGoogle Scholar
  14. 14.
    Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70: 7992.8002.Google Scholar
  15. 15.
    Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014; 74: 2270–82.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2015; 1: 582–91.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015; 68(6): 939–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA oncology. 2016; 2: 1441–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    McShane LM. In pursuit of greater reproducibility and credibility of early clinical biomarker research. Clin Transl Sci. 2017; 10(2): 58–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer. Eur Urol. 2017; 71: 1–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): expanded analysis of the Johns Hopkins cohort. J Clin Oncol. 2016; 34(suppl; abstr 5012).Google Scholar
  22. 22.
    Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol. 2017; 71(1): 4.6: Unsplicing a Conflict.Google Scholar
  23. 23.
    Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate. 2016; 76: 1484–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2017

Authors and Affiliations

  1. 1.Klinik für UrologieUniversitätsklinikum MünsterMünsterDeutschland

Personalised recommendations